摘要
目的探讨米氮平治疗老年期腔隙性脑梗死伴发抑郁和焦虑的临床疗效和安全性。方法将60例符合"中国精神障碍分类和诊断标准"(第3版)(CCMD-3)中抑郁症诊断标准的老年期腔隙性脑梗死患者在内科药物基础上联合米氮平治疗,剂量30～45 mg·d^(-1),疗程6 wk。采用汉密尔顿抑郁量表17项(HAMD-17)、汉密尔顿焦虑量表(HAMA)和副反应量表(TESS)在治疗前和治疗1、2、4、6 wk末评定临床疗效及不良反应。结果治疗wk 1末HAMD-17、HAMA评分较治疗前比较均明显下降(P<0.05);wk 2、4、6末评分持续下降,与治疗前比较有非常显著差异(P<0.01);治疗wk 1末TESS评分较治疗前比较明显升高(P<0.05),wk 2、4、6末评分与治疗前比较无显著差异(P>0.05),且不良反应轻微,耐受性较好。结论米氮平治疗老年期腔隙性脑梗死伴发抑郁和焦虑患者临床疗效良好,起效快且不良反应轻微。
AIM To explore the efficacy and safety of mirtazapine on depression and anxiety accompanied with brain lacunar infarction in the elderly. METHODS A total of 60 old patients suffered from brain lacunar infarction in line with the CCMD-3 diagnostic criteria were treated with mirtazapine 30 - 45 mg .d-l based on a medical drug for 6 wk, and all patients were evaluated with HAMD-17, HAMA and TESS to assessed the efficacy and adverse reactions. RESULTS The scores of HAMD-17 and HAMA decreased significantly 1 wk after the treatment （P 〈 0.05） compared with those in baseline, with very significant differences between wk 2, 4, 6 and the baseline respectively （P 〈 0.01）. The score of TESS decreased significantly 1 wk after the treatment （P 〈 0.05） compared with that in baseline, with no significant differences between wk 2, 4, 6 and the baseline respectively （P 〉 0.05）. The adverse reactions were light and well tolerated. CONCLUSION Mirtazapine is effective and safe in treatment of depression and anxiety in old patients accompanied with brain lacunar infarction.
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2012年第3期165-167,共3页
Chinese Journal of New Drugs and Clinical Remedies
关键词
米氮平
脑梗死
抑郁
焦虑
mirtazapine
brain infarction
depression
anxiety
